




RealRate

PHARMACEUTICAL 2020

Zymeworks BC Inc
Rank 147 of 363



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Zymeworks BC Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Zymeworks BC Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 49% points. The greatest weakness of Zymeworks BC Inc is the variable Other Expenses, reducing the Economic Capital Ratio by 25% points.

The company's Economic Capital Ratio, given in the ranking table, is 274%, being 36% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	311,830
Cost of Goods Sold	0
Intangible Assets	18,073
Liabilities, Current	82,552
Liabilities, Non-Current	6,623
Other Assets	27,202
Other Compr. Net Income	0
Other Expenses	116,086
Other Liabilities	33,349
Other Net Income	5,282
Other Revenues	29,544
Property and Equipment	11,100
Research and Development	0
Selling, General and Administrative Expense	64,177

Output Variable	Value in 1000 USD
Assets	368,205
Liabilities	122,524
Expenses	180,263
Revenues	29,544
Stockholders Equity	245,681
Net Income	-145,437
Comprehensive Net Income	-145,437
BaseVar	352,909
ECR before LimitedLiability	159%
Economic Capital Ratio	274%